Entropy Neurodynamics

Entropy Neurodynamics Equity Growth

The Year-over-Year Equity Growth of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 23.47 %. In the previous year, Year-over-Year Equity Growth was 6.12 % — a change of 283.72% (higher).

Equity Growth

23.47 %

YoY

283.72%

Last updated:

Year-over-Year Equity Growth of Entropy Neurodynamics is 2026 23.47 % . Year-over-Year Equity Growth of Entropy Neurodynamics was 2025 6.12 % . It decreases by 283.72% higher compared to the previous year.

The Entropy Neurodynamics Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
70,540.05 AUD
Jan 1, 2020
-2.00 AUD
Jan 1, 2021
276.03 AUD
Jan 1, 2022
-53.32 AUD
Jan 1, 2023
-53.14 AUD
Jan 1, 2024
36.18 AUD
Jan 1, 2025
6.12 AUD
Jan 1, 2026
23.47 AUD
The Entropy Neurodynamics Equity Growth history
YEAREquity GrowthYoY
23.47 %+283.72%
6.12 %-83.09%
36.18 %-168.08%
-53.14 %-0.32%
-53.32 %-119.32%
276.03 %-13,918.53%
-2.00 %-100.00%
70,540.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Year-over-Year Equity Growth of Entropy Neurodynamics is 23.47 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics